Document:

EX-10.3

 Exhibit 10.3 

REGISTRATION RIGHTS AGREEMENT 

This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 13, 2016, by and among AVEO
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each a “Purchaser” and collectively, the “Purchasers”). 

This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof between the Company and each Purchaser (the
“Purchase Agreement”). 
 NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each of the Purchasers agree as follows: 

1. Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the
meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: 

“Advice” has the meaning set forth in Section 6(d). 

“Affiliate” means, with respect to any person, any other person which directly or indirectly controls, is controlled by, or
is under common control with, such person. 
 “Agreement” has the meaning set forth in the Preamble. 

“Business Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general
transaction of business. 
 “Closing” has the meaning set forth in the Purchase Agreement. 

“Closing Date” has the meaning set forth in the Purchase Agreement. 

“Commission” means the Securities and Exchange Commission. 

“Common Stock” means the common stock of the Company, par value $0.001 per share, and any securities into which such common
stock may hereinafter be reclassified. 
 “Company” has the meaning set forth in the Preamble. 

“Effective Date” means the date that the Registration Statement filed pursuant to Section 2(a) is first declared
effective by the Commission. 
 “Effectiveness Deadline” means, with respect to the Initial Registration Statement or the
New Registration Statement, the ninetieth (90th) calendar day following the Closing Date (or, in the event the Commission reviews and has written comments to the Initial Registration
Statement or the New Registration Statement, the one hundred twentieth (120th) calendar day following the Closing Date); provided, however, that if the Company is notified by the
Commission that the Initial Registration Statement or the New Registration Statement will not be reviewed or is no longer subject to further review and comments, the Effectiveness Deadline as to such Registration Statement shall be the fifth (5th) Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise required above; provided, further, that if the Effectiveness Deadline falls
on a Saturday, Sunday or other day that the Commission is closed for business, the Effectiveness Deadline shall be extended to the next Business Day on which the Commission is open for business. 

 “Effectiveness Period” has the meaning set forth in Section 2(b).

 “Event” has the meaning set forth in Section 2(c). 

“Event Date” has the meaning set forth in Section 2(c). 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 “Filing Deadline” means, with respect to the Initial Registration Statement required to be filed pursuant to
Section 2(a), the thirtieth (30th) calendar day following the Closing Date, provided, however, that if the Filing Deadline falls on a Saturday, Sunday or other day that the
Commission is closed for business, the Filing Deadline shall be extended to the next business day on which the Commission is open for business. 

“Holder” or “Holders” means the holder or holders, as the case may be, from time to time of Registrable
Securities. 
 “Indemnified Party” has the meaning set forth in Section 5(c). 

“Indemnifying Party” has the meaning set forth in Section 5(c). 

“Initial Registration Statement” means the initial Registration Statement filed pursuant to Section 2(a) of this
Agreement. 
 “Liquidated Damages” has the meaning set forth in Section 2(c). 

“Losses” has the meaning set forth in Section 5(a). 

“New Registration Statement” has the meaning set forth in Section 2(a). 

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture,
limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 

“Principal Market” means the Trading Market on which the Common Stock is primarily listed on and quoted for trading, which,
as of the Closing Date, shall be the NASDAQ Global Select Market. 
 “Proceeding” means an action, claim, suit,
investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether commenced or threatened. 

“Prospectus” means the prospectus included in a Registration Statement (including, without limitation, a prospectus that
includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with
respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective
amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 

  
 2 

 “Purchase Agreement” has the meaning set forth in the Recitals. 

“Purchaser” or “Purchasers” has the meaning set forth in the Preamble. 

“Registrable Securities” means all of (i) the Shares, (ii) the Warrant Shares and (iii) any securities issued
or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing, provided, that the Holder has completed and delivered to the Company a Selling Stockholder Questionnaire;
and provided, further, that with respect to a particular Holder, such Holder’s Shares and Warrant Shares shall cease to be Registrable Securities upon the earliest to occur of the following: (A) a sale pursuant to a Registration
Statement or Rule 144 under the Securities Act (in which case, only such security sold by the Holder shall cease to be a Registrable Security); or (B) becoming eligible for resale by the Holder under Rule 144 without the requirement for the
Company to be in compliance with the current public information required thereunder and without volume or manner-of-sale restrictions, pursuant to a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent.

 “Registration Statements” means any one or more registration statements of the Company filed under the Securities Act
that covers the resale of any of the Registrable Securities pursuant to the provisions of this Agreement (including without limitation the Initial Registration Statement, the New Registration Statement and any Remainder Registration Statements),
amendments and supplements to such Registration Statements, including post-effective amendments, all exhibits and all material incorporated by reference or deemed to be incorporated by reference in such Registration Statements. 

“Remainder Registration Statement” has the meaning set forth in Section 2(a). 

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“Rule 415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“SEC Guidance” means (i) any publicly-available written or oral guidance, comments, requirements or requests of the
Commission staff and (ii) the Securities Act. 
 “Securities Act” means the Securities Act of 1933, as amended, and
the rules and regulations promulgated thereunder. 
 “Selling Stockholder Questionnaire” means a questionnaire in the form
attached as Annex B hereto, or such other form of questionnaire as may reasonably be adopted by the Company from time to time. 

  
 3 

 “Shares” means the shares of Common Stock issued or issuable to the Purchasers
pursuant to the Purchase Agreement. 
 “Trading Day” means (i) a day on which the Common Stock is listed or quoted and
traded on its Principal Market (other than the OTC Bulletin Board), or (ii) if the Common Stock is not listed on a Trading Market (other than the OTC Bulletin Board), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC Bulletin Board, or (iii) if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is
quoted in the over-the-counter market as reported in the “pink sheets” by Pink Sheets LLC (or any similar organization or agency succeeding to its functions of
reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall mean a Business Day. 

“Trading Market” means whichever of the New York Stock Exchange, the NYSE Amex Equities (formerly the American Stock
Exchange), the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question. 

“Warrants” means the Warrants issued pursuant to the Purchase Agreement. 

“Warrant Shares” means the shares of Common Stock issued or issuable upon exercise of the Warrants. 

2. Registration. 
 (a) On
or prior to the Filing Deadline, the Company shall prepare and file with the Commission a Registration Statement covering the resale of all of the Registrable Securities not already covered by an existing and effective Registration Statement for an
offering to be made on a continuous basis pursuant to Rule 415 or, if Rule 415 is not available for offers and sales of the Registrable Securities, by such other means of distribution of Registrable Securities as the Holders may reasonably specify
(the “Initial Registration Statement”). The Initial Registration Statement shall be on Form S-3 (except if the Company is then ineligible to register for resale the Registrable Securities on Form S-3, in which case such registration
shall be on such other form available to register for resale the Registrable Securities as a secondary offering) subject to the provisions of Section 2(e) and shall contain (except if otherwise required pursuant to written comments
received from the Commission upon a review of such Registration Statement) the “Plan of Distribution” section attached hereto as Annex A (which may be modified to respond to comments, if any, provided by the Commission).
Notwithstanding the registration obligations set forth in this Section 2, in the event the Commission informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale
as a secondary offering on a single registration statement, the Company agrees to promptly (i) inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the Initial Registration Statement as required
by the Commission and/or (ii) withdraw the Initial Registration Statement and file a new registration statement (a “New Registration Statement”), in either case covering the maximum number of Registrable Securities permitted to
be registered by the Commission, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary offering; provided, however, that prior to filing such amendment or New Registration Statement, the
Company shall be obligated to use its commercially reasonable efforts to advocate with the Commission for the 

  
 4 

 
registration of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation 612.09. Notwithstanding any other
provision of this Agreement and subject to the payment of liquidated damages in Section 2(c), if any SEC Guidance sets forth a limitation of the number of Registrable Securities permitted to be registered on a particular Registration
Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater number of Registrable Securities), unless otherwise directed in writing by a
Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will first be reduced by Registrable Securities not acquired pursuant to the Purchase Agreement (whether pursuant to
registration rights or otherwise), second by Registrable Securities represented by holders of Warrant Shares (applied, in the case that some Warrant Shares may be registered, to the Holders on a pro rata basis based on the total number of
unregistered Warrant Shares held by such Holders) and third by Registrable Securities represented by Shares (applied, in the case that some Shares may be registered, to the Holders on a pro rata basis based on the total number of unregistered Shares
held by such Holders, subject to a determination by the Commission that certain Holders must be reduced first based on the number of Shares held by such Holders). In the event the Company amends the Initial Registration Statement or files a New
Registration Statement, as the case may be, under clauses (i) or (ii) above, the Company will use its commercially reasonable efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company
or to registrants of securities in general, one or more registration statements on Form S-3 or such other form available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement,
as amended, or the New Registration Statement, as amended (the “Remainder Registration Statements”). 
 (b) The Company
shall use its commercially reasonable efforts to cause each Registration Statement to be declared effective by the Commission as soon as practicable and, with respect to the Initial Registration Statement or the New Registration Statement, as
applicable, no later than the Effectiveness Deadline (including filing with the Commission a request for acceleration of effectiveness in accordance with Rule 461 promulgated under the Securities Act), and shall use its commercially reasonable
efforts to keep each Registration Statement continuously effective under the Securities Act until the earlier of (i) such time as all of the Registrable Securities covered by such Registration Statement have been publicly sold by the Holders or
(ii) the date that all Registrable Securities covered by such Registration Statement may be sold by non-affiliates without volume or manner-of-sale restrictions pursuant to Rule 144, without the requirement for the Company to be in
compliance with the current public information requirement under Rule 144 as determined by counsel to the Company pursuant to a written opinion letter to such effect, addressed, delivered and acceptable to the Company’s transfer agent (the
“Effectiveness Period”). The Company shall telephonically request effectiveness of a Registration Statement as of 5:00 P.M. New York City time on a Trading Day. The Company shall promptly notify the Holders via facsimile or
electronic mail file of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness with the Commission, which date of confirmation shall initially be the date requested for
effectiveness of such Registration Statement. The Company shall, by 9:30 A.M. New York City time on the first Trading Day after the Effective Date, file a final Prospectus with the Commission, as required by Rule 424(b). Failure to so notify the
Holders on or before the second Trading Day after such notification or effectiveness or failure to file a final Prospectus as aforesaid shall be deemed an Event under Section 2(c). 

(c) If: (i) the Initial Registration Statement is not filed with the Commission on or prior to the Filing Deadline, (ii) the Initial
Registration Statement or the New Registration Statement, as 

  
 5 

 
applicable, is not declared effective by the Commission (or otherwise does not become effective) for any reason on or prior to the Effectiveness Deadline or (iii) after its Effective Date,
(A) such Registration Statement ceases for any reason (including without limitation by reason of a stop order, or the Company’s failure to update the Registration Statement), to remain continuously effective as to all Registrable
Securities included in such Registration Statement or (B) the Holders are not permitted to utilize the Prospectus therein to resell such Registrable Securities for any reason for more than an aggregate of thirty (30) consecutive calendar
days or sixty (60) calendar days (which need not be consecutive days) during any twelve (12) month period, or (iv) the Company fails to satisfy the current public information requirement pursuant to Rule 144(c)(1) as a result of which
the Holders who are not affiliates are unable to sell Registrable Securities without restriction under Rule 144 (or any successor thereto), (any such failure or breach in clauses (i) through (iv) above being referred to as an
“Event,” and, for purposes of clauses (i), (ii) or (iv), the date on which such Event occurs, or for purposes of clause (iii), the date on which such thirty (30) or sixty (60) calendar day period is exceeded, being
referred to as an “Event Date”), then in addition to any other rights the Holders may have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event
shall not have been cured by such date) until the earlier of (1) the applicable Event is cured or (2) the Registrable Securities are eligible for resale pursuant to Rule 144 without manner of sale or volume restrictions, the Company
shall pay to each Holder an amount in cash, as partial liquidated damages and not as a penalty (“Liquidated Damages”), equal to one and one half percent (1.5%) of the aggregate purchase price paid by such Holder pursuant to the
Purchase Agreement for any unregistered Registrable Securities then held by such Holder. The parties agree that (1) the Company will not be liable for Liquidated Damages under this Agreement with respect to any Warrants or Warrant Shares (prior
to their issuance), (2) notwithstanding anything to the contrary herein or in the Purchase Agreement, no Liquidated Damages shall be payable with respect to any period after the expiration of the Effectiveness Period (except in respect of an
Event described in Section 2(c)(iv) herein), (it being understood that this sentence shall not relieve the Company of any Liquidated Damages accruing prior to the Effectiveness Deadline) and in no event shall, the aggregate amount of
Liquidated Damages (excluding Liquidated Damages payable in respect of an Event described in Section 2(c)(iv) herein) payable to a Holder exceed, in the aggregate, six percent (6%) of the aggregate purchase price paid by such Holder
pursuant to the Purchase Agreement (twelve percent (12%) if the only Event is clause (iv)) and (3) in no event shall the Company be liable in any thirty (30) day period for Liquidated Damages under this Agreement in excess of one and
one half percent (1.5%) of the aggregate purchase price paid by the Holders pursuant to the Purchase Agreement. If the Company fails to pay any Liquidated Damages pursuant to this Section 2(c) in full within ten (10) Business
Days after the date payable, the Company will pay interest thereon at a rate of one and one-half percent (1.5%) per month (or such lesser maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date
such Liquidated Damages are due until such amounts, plus all such interest thereon, are paid in full. The Liquidated Damages pursuant to the terms hereof shall apply on a daily pro-rata basis for any portion of a month prior to the cure of an Event,
except in the case of the first Event Date. The Company shall not be liable for Liquidated Damages under this Agreement as to any Registrable Securities which are not permitted by the Commission to be included in a Registration Statement due solely
to SEC Guidance from the time that it is determined that such Registrable Securities are not permitted to be registered until such time as the provisions of this Agreement as to the Remainder Registration Statements required to be filed hereunder
are triggered, in which case the provisions of this Section 2(c) shall once again apply, if applicable. In such case, the Liquidated Damages shall be calculated to only apply to the percentage of Registrable Securities which are
permitted in accordance with SEC Guidance to be included in such Registration Statement. The Effectiveness Deadline for a Registration Statement shall be extended without default or Liquidated Damages hereunder in the event that the Company’s
failure to obtain the effectiveness of the Registration Statement on a timely basis results from the failure of a Purchaser to timely provide the Company with information requested by the Company and necessary to complete the Registration
Statement in accordance with the requirements of the Securities Act (in which the Effectiveness Deadline would be extended with respect to Registrable Securities held by such Purchaser). 

  
 6 

 (d) Each Holder agrees to furnish to the Company a completed Selling Stockholder Questionnaire
not more than five (5) Trading Days following the date of this Agreement. At least five (5) Trading Days prior to the first anticipated filing date of a Registration Statement for any registration under this Agreement, the Company will
notify each Holder of the information the Company requires from that Holder other than the information contained in the Selling Stockholder Questionnaire, if any, which shall be completed and delivered to the Company promptly upon request and, in
any event, within three (3) Trading Days prior to the applicable anticipated filing date. Each Holder further agrees that it shall not be entitled to be named as a selling securityholder in the Registration Statement or use the Prospectus for
offers and resales of Registrable Securities at any time, unless such Holder has returned to the Company a completed and signed Selling Stockholder Questionnaire and a response to any requests for further information as described in the previous
sentence. If a Holder of Registrable Securities returns a Selling Stockholder Questionnaire or a request for further information, in either case, after its respective deadline, the Company shall use its commercially reasonable efforts to take such
actions as are required to name such Holder as a selling security holder in the Registration Statement or any pre-effective or post-effective amendment thereto and to include (to the extent not theretofore included) in the Registration Statement the
Registrable Securities identified in such late Selling Stockholder Questionnaire or request for further information. Each Holder acknowledges and agrees that the information in the Selling Stockholder Questionnaire or request for further information
as described in this Section 2(d) will be used by the Company in the preparation of the Registration Statement and hereby consents to the inclusion of such information in the Registration Statement. 

(e) In the event that Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall
(i) register the resale of the Registrable Securities on another appropriate form reasonably acceptable to the Holders and (ii) undertake to register the Registrable Securities on Form S-3 promptly after such form is available,
provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission.

 3. Registration Procedures 

In connection with the Company’s registration obligations hereunder, the Company shall: 

(a) Not less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day
prior to the filing of any related Prospectus or any amendment or supplement thereto (except for Annual Reports on Form 10-K, and Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any similar or successor reports), (i) furnish
to the Holder copies of such Registration Statement, Prospectus or amendment or supplement thereto, as proposed to be filed, which documents will be subject to the review of such Holder (it being acknowledged and agreed that if a Holder does not
object to or comment on the aforementioned documents within such five (5) Trading Day or one (1) Trading Day period, as the case may be, then the Holder shall be deemed to have consented to and approved the use of such documents) and
(ii) use commercially reasonable efforts to cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective counsel to each
Holder, to conduct a reasonable investigation within the meaning of the Securities Act. The Company shall not file any Registration Statement or any such Prospectus or any amendments or supplements thereto in a form to which a Holder reasonably
objects in good faith, provided that, the Company is notified of such objection in writing within the five (5) Trading Day or one (1) Trading Day period described above, as applicable. 

  
 7 

 (b) (i) Prepare and file with the Commission such amendments (including post-effective amendments) and supplements, to each Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective as to the
applicable Registrable Securities for its Effectiveness Period; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended,
to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably practicable to any comments received from the Commission with respect to each Registration Statement or any amendment thereto and, as promptly as reasonably possible,
provide the Holders true and complete copies of all correspondence from and to the Commission relating to such Registration Statement that pertains to the Holders as “Selling Stockholders” but not any comments that would result in the
disclosure to the Holders of material and non-public information concerning the Company; and (iv) comply with the provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a
Registration Statement until such time as all of such Registrable Securities shall have been disposed of (subject to the terms of this Agreement) in accordance with the intended methods of disposition by the Holders thereof as set forth in such
Registration Statement as so amended or in such Prospectus as so supplemented; provided, however, that each Holder shall be responsible for the delivery of the Prospectus to the Persons to whom such Holder sells any of the Shares or the
Warrant Shares (including in accordance with Rule 172 under the Securities Act), and each Holder agrees to dispose of Registrable Securities in compliance with the “Plan of Distribution” described in the Registration Statement and
otherwise in compliance with applicable federal and state securities laws. In the case of amendments and supplements to a Registration Statement which are required to be filed pursuant to this Agreement (including pursuant to this
Section 3(b)) by reason of the Company filing a report on Form 10-K, Form 10-Q or Form 8-K or any analogous report under the Exchange Act, the Company shall have incorporated such report by reference into such Registration Statement, if
applicable, or shall file such amendments or supplements with the Commission on the same day on which the Exchange Act report which created the requirement for the Company to amend or supplement such Registration Statement was filed. 

(c) Notify the Holders (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied by an instruction to
suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably practicable (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person)
confirm such notice in writing no later than one (1) Trading Day following the day: (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is
proposed to be filed; (B) when the Commission notifies the Company whether there will be a “review” of such Registration Statement and whenever the Commission comments in writing on any Registration Statement (in which case the
Company shall provide to each of the Holders true and complete copies of all comments that pertain to the Holders as a “Selling Stockholder” or to the “Plan of Distribution” and all written responses thereto, but not information
that the Company believes would constitute material and non-public information); and (C) with respect to each Registration Statement or any post-effective amendment, when the same has become effective;
(ii) of any request by the Commission or any other Federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information that pertains to the Holders as “Selling
Stockholders” or the “Plan of Distribution”; (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or
all of the Registrable Securities or the initiation of any Proceedings for that purpose; (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the
Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for 

  
 8 

 
such purpose; (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement
made in such Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to such Registration Statement, Prospectus or other
documents so that, in the case of such Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make
the statements therein (in the case of any Prospectus, form of prospectus or supplement thereto, in light of the circumstances under which they were made), not misleading and (vi) of the occurrence or existence of any pending corporate
development with respect to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or
Prospectus, provided that, any and all such information shall remain confidential to each Holder until such information otherwise becomes public, unless disclosure by a Holder is required by law; and provided, further, that
notwithstanding each Holder’s agreement to keep such information confidential, each such Holder makes no acknowledgement that any such information is material, non-public information. 

(d) Use commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order suspending the
effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, as soon as practicable. 

(e) If requested by a Holder, furnish to such Holder, without charge, at least one conformed copy of each Registration Statement and each
amendment thereto and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission; provided, that the Company shall
have no obligation to provide any document pursuant to this clause that is available on the Commission’s EDGAR system. 
 (f) Prior to
any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from the registration or
qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification
(or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement;
provided, that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or
file a general consent to service of process in any such jurisdiction. 
 (g) If requested by a Holder, cooperate with such Holder to
facilitate the timely preparation and delivery of certificates or book-entry statements representing Registrable Securities to be delivered to a transferee pursuant to the Registration Statement, which certificates or book-entry statements shall be
free, to the extent permitted by the Purchase Agreement and under law, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holders may reasonably request. 

(h) Following the occurrence of any event contemplated by Section 3(c), as promptly as reasonably practicable (taking into account
the Company’s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event), prepare a 

  
 9 

 
supplement or amendment, including a post-effective amendment, to the affected Registration Statements or a supplement to the related Prospectus or any
document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, no Registration Statement nor any Prospectus will contain an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, form of prospectus or supplement thereto, in light of the circumstances under which they were made), not misleading.
If the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section 3(c) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall
suspend use of such Prospectus. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company shall be entitled to exercise its right under this
Section 3(h) to suspend the availability of a Registration Statement and Prospectus, subject to the payment of Liquidated Damages otherwise required pursuant to Section 2(c), for a period not to exceed sixty
(60) calendar days (which need not be consecutive days) in any twelve (12) month period. 
 (i) The Company may require each
selling Holder to furnish to the Company a certified statement as to (i) the number of shares of Common Stock beneficially owned by such Holder and any Affiliate thereof, (ii) any Financial Industry Regulatory Authority
(“FINRA”) affiliations, (iii) any natural persons who have the power to vote or dispose of the common stock and (iv) any other information as may be requested by the Commission, FINRA or any state securities commission.
During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of Registrable Securities because any Holder fails to furnish such information within three (3) Trading Days of the Company’s
request, any Liquidated Damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise occur solely because of such delay shall be suspended as to such Holder only, until such information is delivered
to the Company. 
 (j) The Company shall cooperate with any registered broker through which a Holder proposes to resell its Registrable
Securities in effecting a filing with FINRA pursuant to FINRA Rule 2710 as requested by any such Holder and the Company shall pay the filing fee required for the first such filing within two (2) Business Days of the request therefor. 

4. Registration Expenses. All fees and expenses incident to the Company’s performance of or compliance with its obligations under
this Agreement (excluding any underwriting discounts and selling commissions and all legal fees and expenses of legal counsel for any Holder) shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration
Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses (A) with respect to filings required to be
made with any Trading Market on which the Common Stock is then listed for trading, (B) with respect to compliance with applicable state securities or Blue Sky laws (including, without limitation, fees and disbursements of counsel for the
Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities and determination of the eligibility of the Registrable Securities for investment under the laws of such jurisdictions as requested by the Holders) and
(C) if not previously paid by the Company in connection with Section 3(j) above, with respect to any filing that may be required to be made by any broker through which a Holder intends to make sales of Registrable Securities with
FINRA pursuant to the FINRA Rule 5110, so long as the broker is receiving no more than a customary brokerage commission in connection with such sale, (ii) printing expenses (including, without limitation, expenses of printing certificates for
Registrable Securities and of printing prospectuses if the printing of prospectuses is reasonably requested by the Holders of a majority of the Registrable Securities included in the Registration Statement), (iii) messenger, telephone and
delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in
connection with the 

  
 10 

 
consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the
transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in
connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any underwriting, broker or similar fees or commissions of any Holder or, except to the
extent provided for in the Transaction Documents, any legal fees or other costs of the Holders. 
 5. Indemnification. 

(a) Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify, defend and hold
harmless each Holder, the officers, directors, agents, partners, members, managers, stockholders, Affiliates and employees of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act) and the officers, directors, partners, members, managers, stockholders, agents and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all
losses, claims, damages, liabilities, costs (including, without limitation, reasonable costs of preparation and investigation and reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred, that arise out of
or are based upon (i) any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or
arising out of or relating to any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in light of
the circumstances under which they were made) not misleading, or (ii) any violation or alleged violation by the Company of the Securities Act, Exchange Act or any state securities law or any rule or regulation thereunder, in connection with the
performance of its obligations under this Agreement, except to the extent, but only to the extent, that (A) such untrue statements, alleged untrue statements, omissions or alleged omissions are based solely upon information regarding such
Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and
approved in writing by such Holder expressly for use in the Registration Statement, such Prospectus or such form of Prospectus or in any amendment or supplement thereto (it being understood that each Holder has approved Annex A hereto for
this purpose) or (B) in the case of an occurrence of an event of the type specified in Section 3(c)(iii)-(vi), related to the use by a Holder of an outdated or defective Prospectus after the Company has notified such Holder
in writing that the Prospectus is outdated or defective and prior to the receipt by such Holder of the Advice contemplated and defined in Section 6(d) below, to the extent that following the receipt of the Advice the misstatement or
omission giving rise to such Loss would have been corrected or (C) to the extent that any such Losses arise out of the Purchaser’s (or any other indemnified Person’s) failure to send or give a copy of the Prospectus or supplement (as
then amended or supplemented), if required, pursuant to Rule 172 under the Securities Act (or any successor rule) to the Persons asserting an untrue statement or alleged untrue statement or alleged untrue statement or omission or alleged omission at
or prior to the written confirmation of the sale of Registrable Securities to such Person if such statement or omission was corrected in such Prospectus or supplement. The Company shall notify the Holders promptly of the institution, threat or
assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf
of an Indemnified Party (as defined in Section 5(c)) and shall survive the transfer of the Registrable Securities by the Holders. 

  
 11 

 (a) Indemnification by Holders. Each Holder shall, severally and not jointly, indemnify
and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers,
agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising out of or are based solely upon any untrue or alleged untrue statement of a material fact contained
in any Registration Statement, any Prospectus, or any form of prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be
stated therein or necessary to make the statements therein (in the case of any Prospectus, or any form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading (i) to the extent that such
untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein or (ii) to the extent that such information relates to such Holder or such
Holder’s proposed method of distribution of Registrable Securities and was reviewed and approved in writing by such Holder expressly for use in a Registration Statement (it being understood that the Holder has approved Annex A hereto for
this purpose), such Prospectus or such form of Prospectus or in any amendment or supplement thereto or (iii) in the case of an occurrence of an event of the type specified in Section 3(c)(iii)-(vi), to the extent related to
the use by such Holder of an outdated or defective Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior to the receipt by such Holder of the Advice contemplated in
Section 6(d)In no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder upon the sale of the Registrable Securities giving rise to such
indemnification obligation. 
 (b) Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any
Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying
Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all reasonable fees and expenses incurred in connection with defense thereof;
provided, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined
by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party. 

An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses; (2) the Indemnifying Party shall have failed promptly to
assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (3) the named parties to any such Proceeding (including any impleaded parties) include both such
Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest exists if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if
such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying 

  
 12 

 
Party, the Indemnifying Party shall not have the right to assume the defense thereof and such counsel shall be at the expense of the Indemnifying Party); provided, that the Indemnifying
Party shall not be liable for the fees and expenses of more than one separate firm of attorneys at any time for all Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its
written consent, which consent shall not be unreasonably withheld, delayed or conditioned. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which
any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding. 

Subject to the terms of this Agreement, all fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent
incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section 5) shall be paid to the Indemnified Party, as incurred, within twenty (20) Trading Days of written
notice thereof to the Indemnifying Party; provided, that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such Indemnified Party is finally
judicially determined to not be entitled to indemnification hereunder). The failure to deliver written notice to the Indemnifying Party within a reasonable time of the commencement of any such action shall not relieve such Indemnifying Party of any
liability to the Indemnified Party under this Section 5, except to the extent that the Indemnifying Party is materially and adversely prejudiced in its ability to defend such action. 

(c) Contribution. If a claim for indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party
or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses,
in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable
considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or
omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity
to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys’ or other
reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section 5 was available to
such party in accordance with its terms. 
 The parties hereto agree that it would not be just and equitable if contribution pursuant to
this Section 5(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding the provisions
of this Section 5(d), (A) no Holder shall be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by such Holder from the sale of the Registrable Securities subject
to the Proceeding exceeds the amount of any damages that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission and (B) no contribution will be made under
circumstances where the maker of such contribution would not have been required to indemnify the Indemnified Party under the fault standards set forth in this Section 5. No person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 

  
 13 

 The indemnity and contribution agreements contained in this Section 5 are in addition to any
liability that the Indemnifying Parties may have to the Indemnified Parties and are not in diminution or limitation of the indemnification provisions under the Purchase Agreement. 

6. Miscellaneous. 
 (a)
Remedies. In the event of a breach by the Company or by a Holder of any of their obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under
this Agreement, including recovery of damages, will be entitled to specific performance of its rights under this Agreement. The Company and each Holder agree that monetary damages would not provide adequate compensation for any losses incurred by
reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall waive the defense that a remedy at law would be adequate.

 (b) No Piggyback on Registrations; Prohibition on Filing Other Registration Statements. Except and to the extent specified in the
Disclosure Schedules to the Purchase Agreement, neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in a Registration Statement other than the
Registrable Securities and the Company shall not prior to the Effective Date enter into any agreement providing any such right to any of its security holders. The Company shall not file with the Commission a registration statement relating to an
offering for its own account under the Securities Act of any of its equity securities other than a registration statement on Form S-8 or, in connection with an acquisition, on Form S-4 until the earlier of (i) the date that is thirty
(30) days after the Initial Registration Statement or New Registration Statement, as the case may be, is declared effective or (ii) the date that all Registrable Securities are eligible for resale by non-affiliates without volume or manner
of sale restrictions under Rule 144 and without the requirement for the Company to be in compliance with the current public information requirements under Rule 144. For the avoidance of doubt, the Company shall not be prohibited from preparing and
filing with the Commission a registration statement relating to an offering of Common Stock by existing stockholders of the Company under the Securities Act pursuant to the terms of registration rights held by such stockholder or from filing
amendments to registration statements filed prior to the date of this Agreement. 
 (c) Compliance. Each Holder covenants and agrees
that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it (unless an exemption therefrom is available) in connection with sales of Registrable Securities pursuant to the Registration Statement and shall
sell the Registrable Securities only in accordance with a method of distribution described in the Registration Statement 
 (d)
Discontinued Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 3(c)(iii)-(vi), such
Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the “Advice”) by the Company that the use of the applicable Prospectus (as it may have been
supplemented or amended) may be resumed. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company agrees and acknowledges that any periods during
which the Holder is required to discontinue the disposition of the Registrable Securities hereunder shall be subject to the provisions of Section 2(c). 

(e) No Inconsistent Agreements. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the
Company or any of its Subsidiaries, on or after the date hereof, enter into any agreement with respect to its securities, that would have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the
provisions hereof. 

  
 14 

 (f) Amendments and Waivers. The provisions of this Agreement, including the provisions of
this sentence, may not be amended, modified or supplemented, or waived unless the same shall be in writing and signed by the Company and Holders holding no less than a majority of the then outstanding Registrable Securities, provided that any party
may give a waiver as to itself. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of Holders and that does not directly or indirectly affect the
rights of other Holders may be given by Holders of all of the Registrable Securities to which such waiver or consent relates; provided, however, that the provisions of this sentence may not be amended, modified, or supplemented except
in accordance with the provisions of the immediately preceding sentence. 
 (g) Notices. Any and all notices or other communications
or deliveries required or permitted to be provided hereunder shall be delivered as set forth in the Purchase Agreement. 
 (h) Successors
and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. Nothing in this Agreement, express or implied, is intended
to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. The Company may
not assign its rights (except by merger or in connection with another entity acquiring all or substantially all of the Company’s assets) or obligations hereunder without the prior written consent of all the Holders of the then outstanding
Registrable Securities. Each Holder may assign its respective rights hereunder in the manner and to the Persons as permitted under the Purchase Agreement; provided in each case that (i) the Holder agrees in writing with the transferee or
assignee to assign such rights and related obligations under this Agreement, and for the transferee or assignee to assume such obligations, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment,
(ii) the Company is, within a reasonable time after such transfer or assignment, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being
transferred or assigned, (iii) at or before the time the Company received the written notice contemplated by clause (ii) of this sentence, the transferee or assignee agrees in writing with the Company to be bound by all of the provisions
contained herein and (iv) the transferee is an “accredited investor,” as that term is defined in Rule 501 of Regulation D. 

(i) Execution and Counterparts. This Agreement may be executed in two or more counterparts, each of which when so executed shall be
deemed to be an original and, all of which taken together shall constitute one and the same Agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties
need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature were the original thereof. 

(j) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
determined in accordance with the provisions of the Purchase Agreement. 
 (k) Cumulative Remedies. The remedies provided herein are
cumulative and not exclusive of any other remedies provided by law. 

  
 15 

 (l) Severability. If any term, provision, covenant or restriction of this Agreement is
held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected,
impaired or invalidated, and the parties hereto shall use their good faith reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or
restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid,
illegal, void or unenforceable. 
 (m) Headings. The headings in this Agreement are for convenience only and shall not limit or
otherwise affect the meaning hereof. 
 (n) Independent Nature of Purchasers’ Obligations and Rights. The obligations of each
Purchaser under this Agreement are several and not joint with the obligations of any other Purchaser hereunder, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser hereunder. The decision of
each Purchaser to purchase the Securities pursuant to the Transaction Documents has been made independently of any other Purchaser. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any
Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert with
respect to such obligations or the transactions contemplated by this Agreement. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder and that no Purchaser will
be acting as agent of such Purchaser in connection with monitoring its investment in the Securities or enforcing its rights under the Transaction Documents. Each Purchaser shall be entitled to protect and enforce its rights, including, without
limitation, the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. The Company acknowledges that each of the Purchasers has been
provided with the same Registration Rights Agreement for the purpose of closing a transaction with multiple Purchasers and not because it was required or requested to do so by any Purchaser. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 16 

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	AVEO PHARMACEUTICALS, INC.
		
	By:  	 	 /s/ Michael Bailey

		 	Name: Michael Bailey
		 	Title: Chief Executive Officer

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	AVEO PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Keith Ehrlich

		 	Name: Keith Ehrlich
		 	Title: Chief Financial Officer

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	NAME OF INVESTING ENTITY
	
	 Growth Equity, Opportunities Fund IV, LLC

	
	AUTHORIZED SIGNATORY

 
			
		
	By:	 	 /s/ Louis S.Citron

			
	Name:	 	Louis S.Citron
	Title:	 	Vice President
	
	ADDRESS FOR NOTICE
		
	c/o:	 	 New Enterprise Associates, Inc.

			
		
	Street:	 	 1954 Greenspring Drive, Suite 600.

			
		
	City/State/Zip:	 	 Timonium, MD 21093

			
		
	Attention:	 	 Louis S. Citron

 
			
		
	Tel:	 	
                     

 
			
		
	Fax:	 	
                     

 
			
		
	Email:	 	
                     

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	NAME OF INVESTING ENTITY
	
	 New Leaf Growth Fund I, L.P.

	
	AUTHORIZED SIGNATORY

 
			
		
	By:	 	 /s/ Isaac Manke

 
			
	Name:	 	Isaac Manke
	Title:	 	Attorney In Fact
	
	ADDRESS FOR NOTICE
		
	c/o:	 	 New Leaf Growth Fund I, L.P.

			
		
	Street:	 	 7 Times Square, Suite 3502

			
		
	City/State/Zip:	 	 New York, NY 10036

			
		
	Attention:	 	 Isaac Manke

 
			
		
	Tel:	 	
                     

 
			
		
	Fax:	 	
                     

 
			
		
	Email:	 	
                     

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	NAME OF INVESTING ENTITY
	
	 Perceptive Life Sciences Master Fund Ltd.

	
	AUTHORIZED SIGNATORY

 
			
		
	By:	 	 /s/ James A. Mannix

			
	Name:	 	James A. Mannix
	Title:	 	C.O.O
	
	ADDRESS FOR NOTICE
		
	c/o:	 	 Perceptive Advisors LLC

			
		
	Street:	 	 51 Astor Place 10th floor

			
		
	City/State/Zip:	 	 New York NY 10003

 

			
		
	Attention:	 	 Steve Berger

 
			
		
	Tel:	 	
                     

 
			
		
	Fax:	 	
                     

 
			
		
	Email:	 	
                     

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	NAME OF INVESTING ENTITY
	
	 NEXTHERA Capital Master Fund LP

	
	AUTHORIZED SIGNATORY

 
			
		
	By:	 	 /s/ Daniel Malek

 
			
	Name:	 	Daniel Malek
	Title:	 	Managing Member
	
	ADDRESS FOR NOTICE
		
	c/o:	 	 NEXTHERA Capital LP

			
		
	Street:	 	 900 Third Avenue, Suite 1100

			
		
	City/State/Zip:	 	 New York, NY 10022

			
		
	Attention:	 	 Tim Surzyn, CFO/COO

			
		
	Tel:	 	
                     

 
			
		
	Fax:	 	
                     

 
			
		
	Email:	 	
                     

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	NAME OF INVESTING ENTITY
	
	 Hercules Capital, Inc.

	
	AUTHORIZED SIGNATORY

 
			
		
	By:	 	 /s/ Jennifer Choe

 

			
	Name:	 	Jennifer Choe
	Title:	 	Assistant General Counsel
	
	ADDRESS FOR NOTICE
		
	c/o:	 	 Hercules Capital, Inc.

			
		
	Street:	 	 400 Hamilton Avenue, Suite 310

			
		
	City/State/Zip:	 	 Palo Alto, CA 94301

			
		
	Attention:	 	 Legal Department and Bryan Jadot

			
		
	Tel:	 	
                     

 
			
		
	Fax:	 	
                     

 
			
		
	Email:	 	
                     

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	NAME OF INVESTING ENTITY
	
	 DAFNA Lifescience Select LP

	
	AUTHORIZED SIGNATORY

 
			
		
	By:	 	 /s/ Fariba Ghodsian

			
	Name:	 	Fariba Ghodsian
	Title:	 	C.I.O
	
	ADDRESS FOR NOTICE
		
	c/o:	 	 DAFNA Capital Mgmt LLC

			
		
	Street:	 	 10990 Wilshire Blvd Suite 1400

			
		
	City/State/Zip:	 	 Los Angeles, CA 90024

			
		
	Attention:	 	 Fariba Ghodsian

 
			
		
	Tel:	 	  

 
			
		
	Fax:	 	  

 
			
		
	Email:	 	  

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	NAME OF INVESTING ENTITY
	
	 DAFNA Lifescience LP

	
	AUTHORIZED SIGNATORY

 
			
		
	By:	 	 /s/ Fariba Ghodsian

			
	Name:	 	Fariba Ghodsian
	Title:	 	C.I.O
	
	ADDRESS FOR NOTICE
		
	c/o:	 	 DAFNA Capital Mgmt LLC

			
		
	Street:	 	 10990 Wilshire Blvd Suite 1400

			
		
	City/State/Zip:	 	 Los Angeles, CA 90024

			
		
	Attention:	 	 Fariba Ghodsian

 
			
		
	Tel:	 	  

 
			
		
	Fax:	 	  

 
			
		
	Email:	 	  

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	NAME OF INVESTING ENTITY
	
	 Keith S. Ehrlich

	
	AUTHORIZED SIGNATORY

 
			
		
	By:	 	 /s/ Keith Ehrlich

 

			
	Name:	 	Keith Ehrlich
	Title:	 	
	
	ADDRESS FOR NOTICE
		
	c/o:	 	  

 
			
		
	Street:	 	  

 
			
		
	City/State/Zip:	 	  

 
			
		
	Attention:	 	  

 
			
		
	Tel:	 	  

 
			
		
	Fax:	 	  

 
			
		
	Email:	 	  

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	NAME OF INVESTING ENTITY
	
	 Henri A. Termeer

	
	AUTHORIZED SIGNATORY

 
			
		
	By:	 	 /s/ Henri A. Termeer

			
	Name:	 	Henri A. Termeer
	Title:	 	
	
	ADDRESS FOR NOTICE
		
	c/o:	 	  

 
			
		
	Street:	 	  

 
			
		
	City/State/Zip:	 	  

 
			
		
	Attention:	 	  

 
			
		
	Tel:	 	  

 
			
		
	Fax:	 	  

 
			
		
	Email:	 	  

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	NAME OF INVESTING ENTITY
	
	 Michael P Bailey

	
	AUTHORIZED SIGNATORY

 
			
		
	By:	 	 /s/ Michael P Bailey

			
	Name:	 	Michael P Bailey
	Title:	 	President & CEO
	
	ADDRESS FOR NOTICE
		
	c/o:	 	  

 
			
		
	Street:	 	  

 
			
		
	City/State/Zip:	 	  

 
			
		
	Attention:	 	  

 
			
		
	Tel:	 	  

 
			
		
	Fax:	 	  

 
			
		
	Email:	 	  

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	NAME OF INVESTING ENTITY
	
	 ANTHONY B. EVNIN

	
	AUTHORIZED SIGNATORY

 
			
		
	By:	 	 /s/ Anthony B. Evnin

			
	Name:	 	
	Title:	 	
	
	ADDRESS FOR NOTICE
		
	c/o:	 	  

 
			
		
	Street:	 	  

 
			
		
	City/State/Zip:	 	  

 
			
		
	Attention:	 	  

 
			
		
	Tel:	 	  

 
			
		
	Fax:	 	  

 
			
		
	Email:	 	  

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	NAME OF INVESTING ENTITY
	
	 Michael N Needle

	
	AUTHORIZED SIGNATORY

 
			
		
	By:	 	 /s/ Michael N Needle

			
	Name:	 	Michael N Needle
	Title:	 	
	
	ADDRESS FOR NOTICE
		
	c/o:	 	  

 
			
		
	Street:	 	  

 
			
		
	City/State/Zip:	 	  

 
			
		
	Attention:	 	  

 
			
		
	Tel:	 	  

 
			
		
	Fax:	 	  

 
			
		
	Email:	 	  

 ANNEX A 

PLAN OF DISTRIBUTION 
 We are
registering the shares of Common Stock issued to the selling stockholders and issuable upon exercise of the warrants issued to the selling stockholders to permit the resale of these shares of Common Stock by the holders of the shares of Common Stock
and warrants from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling stockholders of the shares of Common Stock. We will bear all fees and expenses incident to our obligation to
register the shares of Common Stock. 
 The selling stockholders may sell all or a portion of the shares of Common Stock beneficially owned
by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the shares of Common Stock are sold through underwriters or broker-dealers, the selling stockholders will be responsible for
underwriting discounts or commissions or agent’s commissions. The shares of Common Stock may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the
over-the-counter market or in transactions otherwise than on these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices
determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The selling stockholders may use any one or more of the following methods when selling shares:

  

	 	•	 	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

  

	 	•	 	block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; 

 

	 	•	 	purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

  

	 	•	 	an exchange distribution in accordance with the rules of the applicable exchange; 

  

	 	•	 	privately negotiated transactions; 

  

	 	•	 	settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part; 

  

	 	•	 	broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; 

  

	 	•	 	through the writing or settlement of options or other hedging transactions, whether such options are listed on an options exchange or otherwise; 

 

	 	•	 	a combination of any such methods of sale; and 

  

	 	•	 	any other method permitted pursuant to applicable law. 

 The selling stockholders also may
resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, as permitted by that rule, or Section 4(1) under the Securities Act, if available, rather than under this prospectus, provided
that they meet the criteria and conform to the requirements of those provisions. 

 Broker-dealers engaged by the selling stockholders may
arrange for other broker-dealers to participate in sales. If the selling stockholders effect such transactions by selling shares of Common Stock to or through underwriters, broker-dealers or agents, such
underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions from purchasers of the shares of Common Stock for whom they may act as agent or to whom
they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in
compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.01. 

In connection with sales of the shares of Common Stock or otherwise, the selling stockholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the shares of Common Stock in the course of hedging in positions they assume. The selling stockholders may also sell shares of Common Stock short and if such
short sale shall take place after the date that this Registration Statement is declared effective by the Commission, the selling stockholders may deliver shares of Common Stock covered by this prospectus to close out short positions and to return
borrowed shares in connection with such short sales. The selling stockholders may also loan or pledge shares of Common Stock to broker-dealers that in turn may sell such shares, to the extent permitted by applicable law. The selling stockholders may
also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered
by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). Notwithstanding the foregoing, the selling stockholders have been
advised that they may not use shares registered on this registration statement to cover short sales of our common stock made prior to the date the registration statement, of which this prospectus forms a part, has been declared effective by the SEC.

 The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the warrants or shares of Common
Stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of Common Stock from time to time pursuant to this prospectus or any amendment to this prospectus
under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933, as amended, amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under
this prospectus. The selling stockholders also may transfer and donate the shares of Common Stock in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for
purposes of this prospectus. 
 The selling stockholders and any broker-dealer or agents participating in the distribution of the shares of
Common Stock may be deemed to be “underwriters” within the meaning of Section 2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such
broker-dealer or agent and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Selling Stockholders who are “underwriters” within the meaning of
Section 2(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities Act including Rule 172 thereunder and may be subject to certain statutory liabilities of, including but not limited to,
Sections 11, 12 and 17 of the Securities Act and Rule 10b-5 under the Securities Exchange Act of 1934, as amended, or the Exchange Act. 

Each selling stockholder has informed the Company that it is not a registered broker-dealer and does not have any written or oral agreement or
understanding, directly or indirectly, with any person to distribute the Common Stock. Upon the Company being notified in writing by a selling stockholder that any material arrangement has been entered into with a broker-dealer for the sale of
common stock through a block trade, 

 
special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule 424(b) under
the Securities Act, disclosing (i) the name of each such selling stockholder and of the participating broker-dealer(s), (ii) the number of shares involved, (iii) the price at which such the shares of Common Stock were sold,
(iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in
this prospectus, and (vi) other facts material to the transaction. In no event shall any broker-dealer receive fees, commissions and markups, which, in the aggregate, would exceed eight percent (8.0%). 

Under the securities laws of some states, the shares of Common Stock may be sold in such states only through registered or licensed brokers or
dealers. In addition, in some states the shares of Common Stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. 

There can be no assurance that any selling stockholder will sell any or all of the shares of Common Stock registered pursuant to the shelf
registration statement, of which this prospectus forms a part. 
 Each selling stockholder and any other person participating in such
distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases
and sales of any of the shares of Common Stock by the selling stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the shares of Common
Stock to engage in market-making activities with respect to the shares of Common Stock. All of the foregoing may affect the marketability of the shares of Common Stock and the ability of any person or entity to engage in market-making activities
with respect to the shares of Common Stock. 
 We will pay all expenses of the registration of the shares of Common Stock pursuant to the
registration rights agreement, including, without limitation, Securities and Exchange Commission filing fees and expenses of compliance with state securities or “blue sky” laws; provided, however, that each selling
stockholder will pay all underwriting discounts and selling commissions, if any and any related legal expenses incurred by it. We will indemnify the selling stockholders against certain liabilities, including some liabilities under the Securities
Act, in accordance with the registration rights agreement, or the selling stockholders will be entitled to contribution. We may be indemnified by the selling stockholders against civil liabilities, including liabilities under the Securities Act,
that may arise from any written information furnished to us by the selling stockholders specifically for use in this prospectus, in accordance with the related registration rights agreements, or we may be entitled to contribution. 

 ANNEX B 

SELLING STOCKHOLDER NOTICE AND QUESTIONNAIRE 

The undersigned holder of shares of the common stock, par value $0.001 per share of AVEO Pharmaceuticals, Inc. (the
“Company”) issued pursuant to a certain Securities Purchase Agreement by and among the Company and the Purchasers named therein, dated as of May 13, 2016 (the “Agreement”), understands that the Company intends
to file with the Securities and Exchange Commission a registration statement on Form S-3 (the “Resale Registration Statement”) for the registration and the resale under Rule 415 of the Securities Act of 1933, as amended (the
“Securities Act”), of the Registrable Securities in accordance with the terms of the Agreement. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Agreement. 

In order to sell or otherwise dispose of any Registrable Securities pursuant to the Resale Registration Statement, a holder of Registrable
Securities generally will be required to be named as a selling stockholder in the related prospectus or a supplement thereto (as so supplemented, the “Prospectus”), deliver the Prospectus to purchasers of Registrable Securities
(including pursuant to Rule 172 under the Securities Act) and be bound by the provisions of the Agreement (including certain indemnification provisions, as described below). Holders must complete and deliver this Notice and Questionnaire in order to
be named as selling stockholders in the Prospectus. Holders of Registrable Securities who do not complete, execute and return this Notice and Questionnaire within five (5) Trading Days following the date of the Agreement (1) will not be
named as selling stockholders in the Resale Registration Statement or the Prospectus and (2) may not use the Prospectus for resales of Registrable Securities.  

Certain legal consequences arise from being named as a selling stockholder in the Resale Registration Statement and the Prospectus. Holders of
Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not named as a selling stockholder in the Resale Registration Statement and the Prospectus. 

NOTICE 
 The undersigned
holder (the “Selling Stockholder”) of Registrable Securities hereby gives notice to the Company of its intention to sell or otherwise dispose of Registrable Securities owned by it and listed below in Item (3), unless otherwise
specified in Item (3), pursuant to the Resale Registration Statement. The undersigned, by signing and returning this Notice and Questionnaire, understands and agrees that it will be bound by the terms and conditions of this Notice and Questionnaire
and the Agreement. 
 The undersigned hereby provides the following information to the Company and represents and warrants that such
information is accurate and complete: 
 QUESTIONNAIRE 
  

	1.	Name. 

  

	 	(a)	Full Legal Name of Selling Stockholder: 

  

			
		 	  

	 	(b)	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities Listed in Item 3 below are held: 

 

			
		 	  

  

	 	(c)	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by the questionnaire): 

 

			
		 	  

  

	2.	Address for Notices to Selling Stockholder: 

  

			
	  

	  

	  

	Telephone:	 	  

			
	Fax:	 	  

			
	Contact Person:	 	  

			
	E-mail address of Contact Person:	 	  

  

	3.	Beneficial Ownership of Registrable Securities Issuable Pursuant to the Purchase Agreement: 

  

	 	(a)	Type and Number of Registrable Securities beneficially owned and issued pursuant to the Agreement: 

  

			
		 	  

		 	  

		 	  

  

	 	(b)	Number of shares of Common Stock to be registered pursuant to this Notice for resale: 

  

			
		 	  

		 	  

		 	  

  

	4.	Broker-Dealer Status: 

  

	 	(a)	Are you a broker-dealer? 

Yes   ̈            No 
  ̈ 
  

	 	(b)	If “yes” to Section 4(a), did you receive your Registrable Securities as compensation for investment banking services to the Company? 

Yes   ̈            No 
  ̈ 

	 	Note:	If no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement. 

  

	 	(c)	Are you an affiliate of a broker-dealer? 

Yes   ̈            No 
  ̈ 
  

	 	Note:	If yes, provide a narrative explanation below: 

  

			
		 	  

		 	  

  

	 	(c)	If you are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you
had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities? 

Yes   ̈            No 
  ̈ 
  

	 	Note:	If no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement. 

			
		 	

  

	5.	Beneficial Ownership of Other Securities of the Company Owned by the Selling Stockholder. 

Except as set forth below in this Item 5, the undersigned is not the beneficial or registered owner of any securities of the Company
other than the Registrable Securities listed above in Item 3. 
 Type and amount of other securities beneficially owned: 

 

			
		 	  

		 	  

  

	6.	Relationships with the Company: 

 Except as set forth below, neither the undersigned
nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its
predecessors or affiliates) during the past three years. 
 State any exceptions here: 

 

			
		 	  

		 	  

	7.	Plan of Distribution: 

 The undersigned has reviewed the form of Plan of Distribution
attached as Annex A to the Registration Rights Agreement, and hereby confirms that, except as set forth below, the information contained therein regarding the undersigned and its plan of distribution is correct and complete. 

State any exceptions here: 
  

			
		 	  

		 	  

 *********** 
 The
undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof and prior to the effective date of any applicable Resale Registration Statement. All
notices hereunder and pursuant to the Agreement shall be made in writing, by hand delivery, confirmed or facsimile transmission, first-class mail or air courier guaranteeing overnight delivery at the address set forth below. In the absence of any
such notification, the Company shall be entitled to continue to rely on the accuracy of the information in this Notice and Questionnaire. 
 By signing
below, the undersigned consents to the disclosure of the information contained herein in its answers to Items (1) through (7) above and the inclusion of such information in the Resale Registration Statement and the Prospectus. The
undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of any such Registration Statement and the Prospectus. 

By signing below, the undersigned acknowledges that it understands its obligation to comply, and agrees that it will comply, with the provisions of the
Exchange Act and the rules and regulations thereunder, particularly Regulation M in connection with any offering of Registrable Securities pursuant to the Resale Registration Statement. The undersigned also acknowledges that it understands that the
answers to this Questionnaire are furnished for use in connection with Registration Statements filed pursuant to the Registration Rights Agreement and any amendments or supplements thereto filed with the Commission pursuant to the Securities Act.

 The undersigned hereby acknowledges and is advised of the following Interpretation A.65 of the July 1997 SEC Manual of Publicly Available Telephone
Interpretations regarding short selling: 
 “An Issuer filed a Form S-3 registration statement for a secondary offering of common stock which is not
yet effective. One of the selling stockholders wanted to do a short sale of common stock “against the box” and cover the short sale with registered shares after the effective date. The issuer was advised that the short sale could not be
made before the registration statement become effective, because the shares underlying the short sale are deemed to be sold at the time such sale is made. There would, therefore, be a violation of Section 5 if the shares were effectively sold
prior to the effective date.” 
 By returning this Questionnaire, the undersigned will be deemed to be aware of the foregoing interpretation. 

I confirm that, to the best of my knowledge and belief, the foregoing statements (including without limitation the answers to this Questionnaire) are correct.

 IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Questionnaire to be executed and
delivered either in person or by its duly authorized agent. 
  

							
	Dated:
                                    	 		 	Beneficial Owner:	 	  

 

							
		 		 	By:	 	  

		 		 		 	Name:
		 		 		 	Title:

 PLEASE FAX A COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, TO:

 Chad Huber 
 Piper
Jaffray & Co. 
 345 Park Avenue 

New York, NY 10154 
 Tel:
212-284-9573 
 Email: chad.e.huber@pjc.comEX-10.4

 Exhibit 10.4 

AMENDMENT NO. 4 TO LOAN AND SECURITY AGREEMENT 

This AMENDMENT NO. 4 TO LOAN AND SECURITY AGREEMENT (this “Amendment”), is entered into this 13th day of May, 2016 (the “Effective Date”), by and among (a) AVEO PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), (b) HERCULES CAPITAL,
INC., formerly known as HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation in its capacity as administrative agent for itself and the Lender (as defined herein) (in such capacity, the “Agent”), and
(c) (i) HERCULES TECHNOLOGY III, L.P., a Delaware limited partnership and (ii) the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (as defined below) (collectively,
referred to as “Lender”). Capitalized terms used herein without definition shall have the same meanings given them in the Loan Agreement (as defined below). 

WHEREAS, Borrower and Lender are parties to a certain Loan and Security Agreement, dated as of May 28, 2010, as amended by that
certain Amendment No. 1 to Loan and Security Agreement, dated as of December 21, 2011, as amended by that certain Amendment No. 2 to Loan and Security Agreement, dated as of March 31, 2012, and as further amended by that certain
Amendment No. 3 to Loan and Security Agreement, dated as of September 24, 2014 (as the same may from time to time be further amended, modified or supplemented in accordance with its terms, the “Loan Agreement”); 

WHEREAS, the Borrower has repaid all Term Loan Advances in accordance with the terms of the Loan Agreement; and 

WHEREAS, in accordance with Section 11.3 of the Loan Agreement, Borrower and Lender desire to amend the Loan Agreement as provided
herein. 
 NOW THEREFORE, in consideration of the mutual agreements contained in the Loan Agreement and herein and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1.
Defined Terms. Terms not otherwise defined herein which are defined in the Loan Agreement shall have the same respective meanings herein as therein. 

2. Amendments to Loan Agreement. Subject to the satisfaction of the conditions set forth in Section 4 of this Amendment,
the Loan Agreement is hereby amended as follows: 
 (a) The Loan Agreement shall be amended by (i) deleting
“and” at the end of Recital F, (ii) changing “.” to “;” at the end of Recital G; and (iii) inserting the following new provisions to appear as Recitals H and G thereof: 

“H. Borrower has requested Lender to make available to Borrower terms loans (each a “2016 Term Loan
Advance” and collectively “2016 Term Loan Advances”) in aggregate principal amount of Ten Million Dollars ($10,000,000) comprised of (i) a term loan (the “2016 Term A Loan Advance”) in an aggregate
principal amount of Five Million Dollars ($5,000,000), and (ii) a term loan (the “2016 Term B Loan Advance”) in an aggregate principal amount of Five Million Dollars ($5,000,000); and 

G. Lender is willing to make the 2016 Term Loan Advances on the terms and conditions set forth in this Agreement.” 

(b) The Loan Agreement shall be amended by inserting the following new definitions to appear alphabetically in Section 1.1
(Definitions and Rules of Construction) thereof: 
 “2016 Closing Date” May 13, 2016. 

  
 1 

 “2016 End of Term Charge” has the meaning given to it in Section 2.5
hereof. 
 “2016 Facility Fee” means One Hundred Thousand Dollars ($100,000.00). 

“2016 Prepayment Charge” has the meaning given to it in Section 2.4 hereof.  

“2016 Term A Loan Advance” has the meaning given to it in Recital H hereof. 

“2016 Term B Loan Advance” has the meaning given to it in Recital H hereof 

“2016 Term Loan Advance” or “2016 Term Loan Advances” has the meaning given to it in Recital H hereof. 

“2016 Term Loan A Funding Event” means confirmation by Lender, that Borrower has received after the 2016 Closing Date,
unrestricted and unencumbered gross cash proceeds in an amount equal to or greater than Fifteen Million Dollars ($15,000,000) resulting from the issuance and sale by Borrower of its equity securities to one or more investors reasonably acceptable to
Agent. 
 “2016 Term Loan Amortization Date” means July 1, 2017; provided, however, that if the 2016 Term Loan B
Funding Event occurs prior to July 1, 2017, at the request of Borrower, the 2016 Term Loan Amortization Date shall be January 1, 2018. 

“2016 Term Loan B Funding Event” means confirmation by Lender, in Lender’s reasonable discretion, that Borrower has
achieved the following: (i) satisfactory developmental progression on a minimum of two (2) clinical programs (other than the Phase 3 clinical trial of Tivozanib for the treatment of renal cell carcinoma for patients in the third-line
setting (the “US Phase III (Tivo)”) that are either managed directly by Borrower or funded, in whole or in part, by the Borrower, and (ii) on the Advance Date of the 2016 Term Loan B Advance, Borrower shall have unrestricted
Cash equal to or greater than Twenty-Five Million Dollars ($25,000,000). 
 “2016 Term Loan Commitment” means as to any
Lender, the obligation of such Lender, if any, to make 2016 Term Loan Advances to Borrower in a principal amount not to exceed the amount set forth under the heading “2016 Term Loan Commitment” opposite such Lender’s name on
Schedule 1.1. 
 “2016 Term Loan Interest Rate” means the greater of (i) 11.90% and (ii) 11.90% plus the
Prime Rate; provided, however, that in no event shall the 2016 Term Loan Interest Rate exceed fifteen percent (15.0%) (provided such limit does not include any Default Rate which may be imposed by Agent). 

“2016 Term Loan Maturity Date” means December 1, 2019 (1st day
of the month following the 42 month anniversary of the 2016 Closing Date). 
 “2016 Warrants” shall mean the warrants
to purchase shares of common stock of the Borrower issued to the Lender by the Borrower on the 2016 Closing Date. 
 “Amendment
No. 4 to the Loan and Security Agreement” is that certain amendment by and among Borrower, Lenders, and Agent dated as of the 2016 Closing Date. 

“Draw Period” is the period of time commencing on and after March 1, 2017 and upon the occurrence of the 2016 Term Loan
B Funding Event and continuing through the earlier to occur of (a) June 30, 2017 or (b) an Event of Default. 

  
 2 

 “Due Diligence Fee” means Fifteen Thousand Dollars ($15,000), which fee is due
to Lender on or prior to the 2016 Closing Date, and shall be deemed fully earned on such date regardless of the early termination of the Amendment No. 4 to the Loan and Security Agreement. 

(c) The following definitions appearing in Section 1.1 thereof are amended in their entirety and replaced with the
following: 
 “2014 Term Loan Amortization Date” means June 1, 2016; provided however, that if the 2016 Term Loan A
Funding Event occurs, at the request of Borrower, the 2014 Term Loan Amortization Date shall be July 1, 2017; and provider further, however, that if the 2016 Term Loan B Funding Event occurs prior to July 1, 2017, at the request of
Borrower, the 2014 Term Loan Amortization Date shall be January 1, 2018. 
 “2014 Term Loan Maturity Date” means
January 1, 2018; provided however, that if the 2016 Term Loan A Funding Event occurs, the 2014 Term Loan Maturity Date is December 1, 2019 1st day of the month following the 42 month
anniversary of the 2016 Closing Date). 
 “Advance(s)” means a Term Loan Advance, a 2014 Term Loan Advance, and/or a
2016 Term Loan Advance, as applicable. 
 “Prime Rate” means the prime rate as reported in The Wall Street Journal minus
5.00%. 
 “Warrant” means, collectively, all warrants to purchase shares of capital stock of the Borrower issued to Lender
by the Borrower (including, without limitation, the New Warrants, the 2014 Warrants, and the 2016 Warrants). 
 (d)
Section 2.1.1(d) (Payment) is amended in its entirety and replaced with the following: 
 “(d) Payment. Prior to the 2014
Term Loan Amortization Date, Borrower will pay interest on the 2014 Term Loan Advance on the first (1st) business day of each month, beginning the month after the applicable Advance Date. Commencing on the 2014 Term Loan Amortization Date, and
continuing on the first (1st) business day of each month thereafter, Borrower shall repay the aggregate principal balance of the 2014 Term Loan Advance that is outstanding on the day immediately preceding the 2014 Term Loan Amortization Date in
equal monthly installments of principal and interest (mortgage style) based on an amortization schedule equal to thirty (30) consecutive months. After any change in the effective rate hereunder, Lender shall recalculate future payments of
principal and interest to fully amortize the outstanding principal amount over the remaining scheduled monthly payments hereunder prior to the 2014 Term Loan Maturity Date (and Lender will provide subsequent notice to Borrower of any such
recalculations). The entire 2014 Term Loan Advance unpaid principal balance and all accrued but unpaid interest hereunder, and all other Secured Obligations with respect to the 2014 Term Loan Advance, shall be due and payable on the 2014 Term Loan
Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the Borrower’s account as authorized on the ACH
Authorization on each payment date of all periodic obligations payable to Lender under the 2014 Term Loan Advance. Once repaid, the 2014 Term Loan Advance or any portion thereof may not be reborrowed.” 

(e) The Loan Agreement is amended by inserting immediately after Section 2.1.1 the following new provision to appear as
Section 2.1.2 (2016 Term Loan) thereof: 

  
 3 

 “2.1.2 2016 Term Loan. 

(a) Advance. Subject to the terms and conditions of this Agreement, on the date that the 2016 Term Loan A Funding Event
occurs, Borrower shall request and Lender will make, in an amount not to exceed its respective 2016 Term Loan Commitment, one (1) 2016 Term A Loan Advance in an amount of Five Million Dollars ($5,000,000). Subject to the terms and conditions of
this Agreement, during the Draw Period, Borrower shall request and Lender will make in an amount not to exceed its respective 2016 Term Loan Commitment, one (1) 2016 Term B Loan Advance in an amount of Five Million Dollars ($5,000,000). 

(b) Advance Request. To obtain a 2016 Term Loan Advance, Borrower shall complete, sign and deliver to Lender an Advance
Request. Lender shall fund the 2016 Term Loan Advance in the manner requested by the Advance Request provided that each of the conditions precedent applicable to such 2016 Term Loan Advance is satisfied as of the requested Advance Date. 

(c) Interest. The principal balance of each 2016 Term Loan Advance shall bear interest thereon from such Advance Date
at the 2016 Term Loan Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed. The 2016 Term Loan Interest Rate will float and change on the day the Prime Rate changes from time
to time. 
 (d) Payment. Prior to the 2016 Term Loan Amortization Date, Borrower will pay interest on the aggregate
principal balance of the 2016 Term Loan Advances on the first (1st) business day of each month, beginning the month after the applicable Advance Date. Commencing on the 2016 Term Loan Amortization Date, and continuing on the first
(1st) business day of each month thereafter, Borrower shall repay the aggregate principal balance of the 2016 Term Loan Advances that are outstanding on the day immediately preceding the 2016 Term Loan Amortization Date in equal monthly
installments of principal and interest (mortgage style) based on an amortization schedule equal to thirty (30) consecutive months. After any change in the effective rate hereunder, Lender shall recalculate future payments of principal and
interest to fully amortize the outstanding principal amount over the remaining scheduled monthly payments hereunder prior to the 2016 Term Loan Maturity Date (and Lender will provide subsequent notice to Borrower of any such recalculations). The
entire principal balance of the 2016 Term Loan Advances and all accrued but unpaid interest hereunder, and all other outstanding Secured Obligations with respect to the 2016 Term Loan Advances, shall be due and payable on 2016 Term Loan Maturity
Date. Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the Borrower’s account as authorized on the ACH
Authorization on each payment date of all periodic obligations payable to Lender under each 2016 Term Loan Advance. Once repaid, a 2016 Term Loan Advance or any portion thereof may not be reborrowed.” 

(f) The last two sentences set forth in Section 2.3 (Default Interest) are amended in their entirety and replaced with the
following: 
 “In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations,
including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set forth in Section 2.1(c), 2.1.1(c), or 2.1.2(c), as applicable, plus five percent (5%) per annum. In
the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth in Section 2.1(c), 2.1.1(c), 2.1.2(c), or Section 2.3, as
applicable.” 

  
 4 

 (g) Section 2.4 (Prepayment) is amended in its entirety and replaced with
the following: 
 “2.4 Prepayment. 

(a) At its option upon at least seven (7) business days prior notice to Lender, Borrower may prepay all, but not less
than all, of the outstanding 2014 Term Loan Advance by paying the entire principal balance, all accrued and unpaid interest, all unpaid Lender’s fees and expenses accrued to the date of the prepayment (including the 2014 End of Term Charge),
together with a prepayment charge equal to the following percentage of the principal 2014 Term Loan Advance amount being prepaid: if such 2014 Term Loan Advance is prepaid in any of the first twelve (12) months following the 2014 Closing Date,
three percent (3.00%); after twelve (12) months following the 2014 Closing Date but prior to twenty four (24) months following the 2014 Closing Date, two percent (2.00%); and thereafter but prior to the 2014 Term Loan Maturity Date, one
percent (1.00%) (each, a “Prepayment Charge”). 
 (b) In addition, at its option upon at least seven
(7) business days prior notice to Lender, Borrower may prepay all, but not less than all, of the outstanding 2016 Term Loan Advance(s) by paying the entire principal balance, all accrued and unpaid interest, all unpaid Lender’s fees and
expenses accrued to the date of the prepayment (including the 2016 End of Term Charge), together with a prepayment charge equal to the following percentage of the principal 2016 Term Loan Advances being prepaid: if such 2016 Term Loan Advance(s) is
prepaid in any of the first twelve (12) months following the 2016 Closing Date, three percent (3.00%); after twelve (12) months following the 2016 Closing Date but prior to twenty four (24) months following the 2016 Closing Date, two
percent (2.00%); and thereafter but prior to the 2016 Term Loan Maturity Date, one percent (1.00%) (each, a “2016 Prepayment Charge”). 

(c) Borrower agrees that each of the Prepayment Charge and 2016 Prepayment Charge is a reasonable calculation of Lender’s
lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early repayment of the 2014 Term Loan Advance and/or 2016 Term Loan Advances. Upon the occurrence of a Change in Control, Borrower shall
prepay the outstanding amount of all principal and accrued interest through the prepayment date and all unpaid Lender’s fees and out-of-pocket expenses under the Loan Documents accrued to the date of the repayment (including the 2014 End of
Term Charge and the 2016 End of Term Charge) together with the applicable Prepayment Charge and/or 2016 Prepayment Charge.” 

(h) Section 2.5 (End of Term Charge) is amended in its entirety and replaced with the following: 

“2.5 End of Term Charges. On the earliest to occur of (i) the 2014 Term Loan Maturity Date, (ii) the date that Borrower
prepays the outstanding 2014 Term Loan Advances, or (iii) the date that the 2014 Term Loan Advances become due and payable, Borrower shall pay Lender a charge equal to Five Hundred Forty Thousand Three Hundred Sixty-Three Dollars and Sixty
Cents ($540,363.60) (the “2014 End of Term Charge”). Notwithstanding the required payment date of such charge, the 2014 End of Term Charge shall have been deemed to have been earned by Lender as of the 2014 Closing Date. In
addition, on the earliest to occur of (i) the 2016 Term Loan Maturity Date, (ii) the date that Borrower prepays the outstanding 2016 Term Loan Advances in full, or (iii) the date that the 2016 Term Loan Advances become due and
payable, Borrower shall pay Lender a charge equal to three percent (3.0%) of the aggregate original principal amount of all 2016 Term Loan Advances extended by Lender (the “2016 End of Term Charge”). Notwithstanding the required
payment date of such charge, the 2016 End of Term Charge shall be deemed to have been earned by Lender as of the 2016 Closing Date.” 

  
 5 

 (i) Section 3 (Security Interests) of the Loan Agreement is amended by
deleting subsection (ii)(D) appearing in the first sentence of Section 3.1 in its entirety and replacing it with the following: 

“(D) [Reserved] and” 

(j) Section 7.13 (Deposit Accounts) is amended in its entirety and replaced with the following: 

“7.13 Deposit Accounts. The Borrower shall not maintain any Deposit Accounts, or accounts holding Investment Property, except
(i) with respect to which Agent has an Account Control Agreement and (ii) a deposit account maintained in the United Kingdom for funding payroll obligations with a balance not to exceed $2,000,000 at any time).” 

(k) Section 7.20 (Financial Covenant) is amended in its entirety and replaced with the following: 

“7.20 Financial Covenant. Borrower shall maintain at all times, commencing on the 2016 Closing Date and continuing through the
date on which the Agent confirms that the US Phase III (Tivo) has been completed with results satisfactory to Agent, in its reasonable discretion, unrestricted Cash equal to or greater than Ten Million Dollars ($10,000,000)” 

(l) Section 12 (Agency). The Loan Agreement is amended by inserting the following new Section 12 thereof: 

“12. AGENCY. Lender hereby irrevocably appoints Hercules Capital, Inc. to act on its behalf as the administrative agent for itself
and the Lender (in such capacity, the “Agent”) hereunder and under the other Loan Documents and authorizes the Agent to take such actions on its behalf and to exercise such powers as are delegated to the Agent by the terms hereof or
thereof, together with such actions and powers as are reasonably incidental thereto.” 
 (m) Exhibit A (Advance
Request) is amended in its entirety and replaced with the Advance Request appearing as Schedule 1 attached hereto. 

(n) The Loan Agreement shall be amended by inserting a new Exhibit B-4 (2016 Term Loan Advance Promissory Note)
appearing as Schedule 2 attached hereto. 
 (o) Exhibit F (Compliance Certificate) is amended in its entirety
and replaced with the Compliance Certificate appearing as Schedule 3 attached hereto. 
 (p) The Loan Agreement shall
be amended by inserting a new Schedule 1.1 (Term Commitments) appearing as Schedule 4 attached hereto. 
 3. Post-Closing
Deliverables. Borrower shall deliver to Agent, on or before thirty (30) days after the Effective Date (the “Post-Closing Delivery Date”): (i) endorsements to the Borrower’s property and liability policies,
which endorsements shall name Agent as lender loss payee and additional insured, and (ii) an Account Control Agreement with each of (x) Comerica Bank and (y) State Street Bank and Trust Company, in form and substance acceptable to
Agent ((i) and (ii) herein collectively, the “Post-Closing Deliverables”). Failure of Borrower to deliver the Post-Closing Deliverables on or before the Post-Closing Delivery Date shall result in an immediate Event of Default
for which there shall be no grace or cure period. 
 4. Waiver of Default. Agent hereby waives Borrower’s existing
default under the Loan Agreement by virtue of Borrower’s failure to comply with the negative covenant (Deposit Accounts) set forth in Section 7.13 thereof for the period commencing on September 24, 2014, through and including the
Post-Closing Delivery Date. Agent’s waiver of Borrower’s compliance of said negative covenant shall apply only to the foregoing specific period. 

  
 6 

 5. Conditions to Effectiveness. Lender and Borrower agree that this
Amendment shall become effective upon the satisfaction of the following conditions precedent, each in form and substance satisfactory to Lender: 

(a) Lender shall have received a fully-executed counterpart of this Amendment signed by Borrower; 

(b) Lender shall have received certified resolutions of Borrower’s board of directors evidencing approval of this
Amendment; 
 (c) Borrower shall have paid to Lender, for the account of Lender, the Due Diligence Fee and the 2016 Facility
Fee; and 
 (d) Lender shall have received payment for all fees and expenses incurred by Lender in connection with this
Amendment, including, but not limited to, all legal fees and expenses. 
 6. Representations and Warranties. The Borrower
hereby represents and warrants to Lender as follows: 
 (a) Representations and Warranties in the Agreement. The
representations and warranties of Borrower set forth in Section 5 of the Loan Agreement are true and correct in all material respects on and as of the date hereof with the same effect as though made on and as of such date, except to the extent
such representations and warranties expressly relate to an earlier date. 
 (b) Authority, Etc. The execution and
delivery by Borrower of this Amendment and the performance by Borrower of all of its agreements and obligations under the Loan Agreement and the other Loan Documents, as amended hereby, are within the corporate authority of Borrower and have been
duly authorized by all necessary corporate action on the part of Borrower. With respect to Borrower, the execution and delivery by Borrower of this Amendment does not and will not require any registration with, consent or approval of, or notice to
any Person (including any governmental authority). 
 (c) Enforceability of Obligations. This Amendment, the Loan
Agreement and the other Loan Documents, as amended hereby, constitute the legal, valid and binding obligations of Borrower enforceable against Borrower in accordance with their terms, except as enforceability is limited by bankruptcy, insolvency,
reorganization, moratorium, general equitable principles or other laws relating to or affecting generally the enforcement of, creditors’ rights and except to the extent that availability of the remedy of specific performance or injunctive
relief is subject to the discretion of the court before which any proceeding therefor may be brought. 
 (d) No
Default. Before and after giving effect to this Amendment (i) no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default, and (ii) no event that has had or
could reasonably be expected to have a Material Adverse Effect has occurred and is continuing. 
 (e) Event of
Default. By its signature below, Borrower hereby agrees that it shall constitute an Event of Default if any representation or warranty made herein should be false or misleading in any material respect when made. 

7. Reaffirmations. Except as expressly provided in this Amendment, all of the terms and conditions of the Loan Agreement and the
other Loan Documents remain in full force and effect. Nothing contained in this Amendment shall in any way prejudice, impair or effect any rights or remedies of Lender under the Loan Agreement and the other Loan Documents. Except as specifically
amended hereby, Borrower hereby ratifies, confirms, and 

  
 7 

 
reaffirms all covenants contained in the Loan Agreement and the other Loan Documents. The Loan Agreement, together with this Amendment, shall be read and construed as a single agreement. All
references in the Loan Documents to the Loan Agreement or any other Loan Document shall hereafter refer to the Loan Agreement or any other Loan Document as amended hereby. 

8. Execution in Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed an
original, but which together shall constitute one instrument. 
 9. Miscellaneous.  

(a) THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF CALIFORNIA,
EXCLUDING CONFLICT OF LAWS PRINCIPLES THAT WOULD CAUSE THE APPLICATION OF LAWS OF ANY OTHER JURISDICTION. 
 (b) The captions
in this Amendment are for convenience of reference only and shall not define or limit the provisions hereof. 
 (c) This
Amendment expresses the entire understanding of the parties with respect to the transactions contemplated hereby. No prior negotiations or discussions shall limit, modify, or otherwise affect the provisions hereof. 

(d) Any determination that any provision of this Amendment or any application hereof is invalid, illegal or unenforceable in
any respect and in any instance shall not affect the validity, legality, or enforceability of such provision in any other instance, or the validity, legality or enforceability of any other provisions of this Amendment. 

[Remainder of this page intentionally left blank] 

  
 8 

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Amendment as of the day and
year first above written. 
  

			
	BORROWER:
	
	AVEO PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Keith Ehrlich

	Name:	 	 Keith Ehrlich

	Its:	 	 Chief Financial Officer

 Accepted in Palo Alto, California: 

 

			
	LENDER:
	
	HERCULES CAPITAL, INC. f/k/a HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	By:	 	 /s/ Jennifer Choe

	Name:	 	 Jennifer Choe

	Its:	 	 Assistant General Counsel

	
	 HERCULES TECHNOLOGY III, L.P.,
 a
Delaware limited partnership

		
	By:	 	 Hercules Technology SBIC
 Management, LLC, its
General Partner

		
	By:	 	Hercules Capital, Inc., its Manager
		
	By:	 	 /s/ Jennifer Choe

	Name:	 	 Jennifer Choe

	Its:	 	 Assistant General Counsel

 Schedule 1 

EXHIBIT A 
 ADVANCE
REQUEST 
  

							
	To:	  	Lender:	  	Date:	  	                , 20        
		  	Hercules Capital, Inc.	  		  	
		  	Hercules Technology III, L.P.	  		  	
		  	400 Hamilton Avenue, Suite 310	  		  	
		  	Palo Alto, CA 94301	  		  	
		  	Facsimile: 650-473-9194	  		  	
		  	Attn: Bryan Jadot	  		  	

 AVEO Pharmaceuticals, Inc. (“Borrower”) hereby requests from Hercules Capital, Inc., f/k/a Hercules
Technology Growth Capital, Inc., and Hercules Technology III, L.P. (collectively, “Lender”) a 2016 Term Loan Advance in the amount of             Dollars
($            ) on             ,             (the “Advance
Date”) pursuant to the Loan and Security Agreement between Borrower and Lender (as amended, the “Agreement”). Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the
Agreement. 
 Please: 
  

							
	(a)	  	 Issue a check payable to Borrower

                          
  or
	  	  
	  	
	(b)	  	Wire Funds to Borrower’s account	  	  
	  	
		  	Bank:	  	  

		  	Address:	  	  

		  	ABA Number:	  	  

		  	Account Number:	  	  

		  	Account Name:	  	  

 Borrower represents that the conditions precedent to the 2016 Term [A/B] Loan Advance set forth in the
Agreement are satisfied and shall be satisfied upon the making of such 2016 Term [A/B] Loan Advance, including but not limited to: (i) that the representations and warranties set forth in the Agreement are and shall be true and correct in all
material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date; (ii) that Borrower is in compliance in all
material respects with all the terms and provisions set forth in each Loan Document on its part to be observed or performed; and (iii) that as of the Advance Date, no fact or condition exists that would (or would, with the passage of time, the
giving of notice, or both) constitute an Event of Default under the Loan Documents. Borrower understands and acknowledges that Lender has the right to review the financial information supporting this representation and, based upon such review in its
sole discretion, Lender may decline to fund the requested 2016 Term Loan Advance. 
 Borrower hereby represents that Borrower’s corporate status and
locations have not changed since the date of the Agreement or, if the Attachment to this Advance Request is completed, are as set forth in the Attachment to this Advance Request. 

Borrower agrees to notify Lender promptly before the funding of the 2016 Term [A/B] Loan Advance if any of the matters which have been
represented above shall not be true and correct on the Advance Date, and if Lender has received no such notice before the Advance Date then the statements set forth above shall be deemed to have been made and shall be deemed to be true and correct
as of the Advance Date. 

 Executed as of the date first written above. 

 

			
	BORROWER:	 	
	  
 AVEO PHARMACEUTICALS, INC.

	SIGNATURE:	 	  

 
			
	TITLE:	 	  

 
			
	PRINT NAME:	 	  

 ATTACHMENT TO ADVANCE REQUEST 

Dated:
                                         
    
 Borrower hereby represents and warrants to Lender that Borrower’s current name and organizational status is as follows: 

 

			
	Name:	  	AVEO Pharmaceuticals, Inc.
	Type of organization:	  	Corporation
	State of organization:	  	Delaware
	Organization file number:	  	3444819

 Borrower hereby represents and warrants to Lender that the street addresses, cities, states and postal codes of its current
locations are as follows: 

 Schedule 2 

EXHIBIT B-4 
  

2016 TERM [A/B] LOAN ADVANCE PROMISSORY NOTE 
  

					
	$[            ],000,000	  	 	Advance Date:          , 20[    ]	  
		  	 	Maturity Date:                 , 20[    ]	  

 FOR VALUE RECEIVED, AVEO Pharmaceuticals, Inc., a Delaware corporation, for itself and each of its
Subsidiaries which executes and delivers a Joinder Agreement (the “Borrower”) hereby promises to pay to the order of Hercules Capital, Inc., f/k/a Hercules Technology Growth Capital, Inc., Hercules Technology III, L.P, or the holder of
this Note (the “Lender”) at 400 Hamilton Avenue, Suite 310, Palo Alto, CA 94301 or such other place of payment as the holder of this 2016 Term Loan Advance Promissory Note (this “Promissory Note”) may specify from time to time in
writing, in lawful money of the United States of America, the principal amount of [ ] Million Dollars ($[ ],000,000) or such other principal amount as Lender has advanced to Borrower, together with interest at a floating per annum rate equal to the
2016 Term Loan Interest Rate (as defined in the Loan Agreement (as defined below)). 
 This Promissory Note is the Note referred to in, and
is executed and delivered in connection with, that certain Loan and Security Agreement dated May 28, 2010, by and between Borrower and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms,
the “Loan Agreement”), and is entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions
thereof. All payments shall be made in accordance with the Loan Agreement. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement shall
constitute a default under this Promissory Note. 
 Borrower waives presentment and demand for payment, notice of dishonor, protest and
notice of protest under the UCC or any applicable law. Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense. This Promissory Note has been negotiated
and delivered to Lender and is payable in the State of California. This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the State of California, excluding any conflicts of law rules or principles that
would cause the application of the laws of any other jurisdiction. 
 BORROWER FOR ITSELF AND 

ON BEHALF OF ITS SUBSIDIARIES: 
 (if such subsidiary executes and
delivers a Joinder Agreement) 
  

	
	AVEO PHARMACEUTICALS, INC.
	By:
	Title:

 Schedule 3 

EXHIBIT F 
 COMPLIANCE
CERTIFICATE 
 Hercules Capital, Inc. 
 Hercules Technology
III, L.P. 
 400 Hamilton Avenue, Suite 310 
 Palo Alto, CA
94301 
 Facsimile: 650-473-9194 
 Attn: Bryan Jadot 

Reference is made to that certain Loan and Security Agreement dated May 28, 2010 and all ancillary documents entered into in connection with such Loan
and Security Agreement all as may be amended from time to time, (hereinafter referred to collectively as the “Loan Agreement”) between Hercules Capital, Inc., f/k/a Hercules Technology Growth Capital, Inc., and Hercules Technology III,
L.P. (collectively, the “Lender”) on the one hand, and AVEO Pharmaceuticals, Inc. (the “Company”) as Borrower, on the other hand. All capitalized terms not defined herein shall have the same meaning as defined in the Loan
Agreement. 
 The undersigned is an officer of the Borrower, knowledgeable of all Borrower financial matters, and is authorized to provide certification of
information regarding the Borrower; hereby certifies, in such capacity as set forth below, that as of the date hereof and in accordance with the terms and conditions of the Loan Agreement, the Borrower is in compliance in all material respects for
the period ending             of all covenants, conditions and terms and hereby reaffirms that all representations and warranties contained therein are true and correct on and as of the
date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of
materiality contained in the Loan Agreement as to such representations and warranties. Attached are the required documents supporting the above certification. The undersigned further certifies, in such capacity as set forth below, that these are
prepared in accordance with GAAP (except for the absence of footnotes with respect to unaudited financial statement and subject to normal year-end adjustments) and are consistent from one period to the next except as explained below. 

 

					
	REPORTING REQUIREMENT	  	REQUIRED	  	CHECK IF ATTACHED
			
	Interim Financial Statements	  	Monthly within 30 days	  	                                   
                               
			
	Interim Financial Statements	  	Quarterly within 30 days	  	                                   
                               
			
	Audited Financial Statements	  	FYE within 90 days	  	                                   
                               
			
	Intellectual Property on Exhibit D	  	Quarterly within 30 days	  	                                   
                               

  

							
	FINANCIAL COVENANT	  	REQUIRED	  	ACTUAL	  	COMPLIES (YES/NO)
				
	Unrestricted Cash	  	$10,000,000	  	                 	  	                 

 BANK ACCOUNTS 
  

			
	Has Borrower opened any new bank accounts	 	
	(since the submission of the prior Compliance Certificate)?	 	(YES/NO)

 If yes, please provide the following information below: 

 

					
	Name of Bank	 	Account Number	 	Purpose of Account
			
	1.	 		 	
			
	2.	 		 	

  

			
	Very Truly Yours,
	
	AVEO PHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	  

	Its:	 	  

 Schedule 4 

SCHEDULE 1.1 
 COMMITMENTS 

 

					
	 LENDER
	  	 2014 TERM COMMITMENT

(2014 Term Loan Advances)
	 
	 Hercules Capital, Inc.
	  	$	10,000,000	  
	 TOTAL COMMITMENTS
	  	$	10,000,000	  

  

					
	 LENDER
	  	 2016 TERM COMMITMENT

(2016 Term Loan A Advance)
	 
	 Hercules Capital, Inc.
	  	 	$5,000,000	  
		
	 	  	
(2016 Term Loan B Advance)
	 
	 Hercules Capital, Inc.
	  	$	5,000,000	  
	 TOTAL COMMITMENTS
	  	$	10,000,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]